2 weeks Ago By ABMN Staff
Equities research analysts at Scotiabank began coverage on shares of UroGen Pharma ( NASDAQ:URGN – Get Free Report ) in a note issued to investors on Wednesday, Marketbeat Ratings reports. The brokerage set a “sector outperform” rating and a $23.00 price target on the stock.
Scotiabank’s price target indicates a potential upside of 137.85% from the company’s current price. URGN has been the subject of several other reports.
D. Boral Capital reissued a “buy” rating and issued a $25.00 price objective on shares of UroGen Pharma in a research report on Monday, March 10th.
LADENBURG THALM/SH SH began coverage on UroGen Pharma in a report on Wednesday, February 19th. They set a “buy” rating and a $31.00 price target on the stock.
Finally, HC Wainwright dropped their target price on shares of UroGen Pharma from $64.00 to $55.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th.
One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $32.
86. View Our Latest Research Report on URGN UroGen Pharma Stock Down 6.9 % UroGen Pharma ( NASDAQ:URGN – Get Free Report ) last released its earnings results on Monday, March 10th.
The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.
11). The business had revenue of $24.57 million for the quarter, compared to analyst estimates of $25.
25 million. On average, analysts anticipate that UroGen Pharma will post -3.12 EPS for the current year.
Insider Activity at UroGen Pharma In other news, insider Mark Schoenberg sold 4,551 shares of the company’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.
14. Following the completion of the sale, the insider now owns 145,666 shares in the company, valued at $1,622,719.24.
This represents a 3.03 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink .
Also, General Counsel Jason Drew Smith sold 7,379 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.
06. Following the transaction, the general counsel now directly owns 26,468 shares in the company, valued at $294,853.52.
The trade was a 21.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here .
5.10% of the stock is owned by insiders. Institutional Investors Weigh In On UroGen Pharma Several institutional investors and hedge funds have recently added to or reduced their stakes in the company.
Charles Schwab Investment Management Inc. increased its position in shares of UroGen Pharma by 9.1% during the third quarter.
Charles Schwab Investment Management Inc. now owns 90,493 shares of the company’s stock valued at $1,149,000 after acquiring an additional 7,576 shares during the last quarter. FMR LLC increased its position in shares of UroGen Pharma by 575.
1% during the 3rd quarter. FMR LLC now owns 23,090 shares of the company’s stock valued at $293,000 after purchasing an additional 19,670 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of UroGen Pharma by 221.
8% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock worth $109,000 after purchasing an additional 5,890 shares during the period. State Street Corp boosted its holdings in shares of UroGen Pharma by 5.
9% in the 3rd quarter. State Street Corp now owns 769,583 shares of the company’s stock worth $9,774,000 after buying an additional 42,907 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in UroGen Pharma during the third quarter valued at about $297,000.
Hedge funds and other institutional investors own 91.29% of the company’s stock. UroGen Pharma Company Profile ( Get Free Report ) UroGen Pharma Ltd.
, a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. Featured Articles Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.
com's FREE daily email newsletter ..
